12 Aug 2020 --- Nestlé Health Science (NHSc) and Israel-based biomedical company Epitomee have entered into a strategic partnership to develop and commercialize a polymer-based ingestible capsule aimed at promoting weight loss and digestive health. Under the terms of the agreement, Epitomee grants NHSc exclusive and global commercial rights to use the product in the weight loss market and potentially to address other disorders, including prediabetes and Type 2 diabetes.
